Bioversys AG Net Assets
Bioversys AG net assets. Based on the latest financial reports, Bioversys AG (BIOV) has net assets worth CHF44.84 Million CHF (≈ $56.69 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF76.91 Million ≈ $97.23 Million USD) and total liabilities (CHF32.07 Million ≈ $40.54 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore BIOV net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF44.84 Million |
| % of Total Assets | 58.3% |
| Annual Growth Rate | 460.58% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of Bioversys AG (2024–2025)
Net assets of Bioversys AG from 2024 to 2025. This chart illustrates how Bioversys AG's net assets have evolved over time, based on quarterly financial data. See Bioversys AG net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Bioversys AG (2024–2025)
The table below shows the annual net assets of Bioversys AG from 2024 to 2025. For live market cap and overall valuation, see Bioversys AG market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CHF59.81 Million ≈ $75.62 Million |
+459.92% |
| 2024-12-31 | CHF10.68 Million ≈ $13.50 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bioversys AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2078500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Bioversys AG Net Assets Breakdown (December 2025)
Bioversys AG net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CHF160.94 Million | 269.08% |
| Total Equity | CHF59.81 Million | 100.00% |
Bioversys AG Competitors by Market Cap
The table below lists competitors of Bioversys AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Novonix Ltd ADR
NASDAQ:NVX
|
$159.30 Million |
|
GalaxyEdge Acquisition Corporation
NYSE:GLED
|
$159.35 Million |
|
Nordfyns Bank A/S
CO:NRDF
|
$159.36 Million |
|
Sahamitr Pressure Container Public Company Limited
BK:SMPC
|
$159.40 Million |
|
Future Money Acquisition Corporation
NASDAQ:FMAC
|
$159.22 Million |
|
Li Peng Enterprise Co Ltd
TW:1447
|
$159.19 Million |
|
LaFayette Acquisition Corp. Ordinary Share
NASDAQ:LAFA
|
$159.18 Million |
|
KT Hitel Corporation. Limited
KQ:036030
|
$159.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bioversys AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 10,682,000 to 59,811,000, a change of 49,129,000 (459.9%).
- Net loss of 21,830,000 reduced equity.
- New share issuances of 76,843,000 increased equity.
- Other factors decreased equity by 5,884,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF-21.83 Million | -36.5% |
| Share Issuances | CHF76.84 Million | +128.48% |
| Other Changes | CHF-5.88 Million | -9.84% |
| Total Change | CHF- | 459.92% |
Book Value vs Market Value Analysis
This analysis compares Bioversys AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.23x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 12.62x to 2.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | CHF1.81 | CHF22.80 | x |
| 2025-12-31 | CHF10.23 | CHF22.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bioversys AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -36.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2728.75%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.52x
- Recent ROE (-36.50%) is above the historical average (-105.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | -175.24% | 0.00% | 0.00x | 3.27x | CHF-19.79 Million |
| 2025 | -36.50% | -2728.75% | 0.01x | 1.52x | CHF-27.81 Million |
Industry Comparison
This section compares Bioversys AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $314,919,321
- Average return on equity (ROE) among peers: -24.72%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bioversys AG (BIOV) | CHF44.84 Million | -175.24% | 0.72x | $159.24 Million |
| Addex Therapeutics Ltd (ADXN) | $16.29 Million | -165.85% | 0.33x | $3.89 Million |
| Bachem Holding AG (BANB) | $384.21 Million | 12.14% | 0.60x | $5.42 Billion |
| BB Biotech AG (BION) | $2.78 Billion | 20.81% | 0.00x | $2.90 Billion |
| Basilea Pharmaceutica AG (BSLN) | $127.94 Million | 31.42% | 1.20x | $686.09 Million |
| Idorsia Ltd (IDIA) | $-660.96 Million | 0.00% | 0.00x | $1.03 Billion |
| MINDMAZE THERAPEUTICS HOLDING SA (MMTX) | $38.34 Million | -25.84% | 0.34x | $28.56 Million |
| Molecular Partners AG (MOLN) | $107.29 Million | -59.45% | 0.61x | $125.91 Million |
| Newron Pharmaceuticals SpA (NWRN) | $21.09 Million | -33.66% | 0.50x | $235.69 Million |
| Relief Therapeutics Holding AG (RLF) | $21.28 Million | -2.05% | 0.67x | $36.33 Million |
About Bioversys AG
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S.… Read more